NCI Funding for HIV and AIDS Malignancies Research

Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine 

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute intends to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes such as multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and KSHV inflammatory cytokine syndrome (KICS), or ameliorate the severity of disease.

Additional Information:
Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine
(U01 Clinical Trial Optional)

The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer

This notice of funding opportunity (NOFO) as a request for applications (RFA), the National Cancer
Institute (NCI) intends to support research that expands the current understanding of the
confluence of cancer stigma and HIV stigma among people with HIV (PWH) diagnosed with cancer;
assesses the impact of these two converging stigmas on cancer outcomes among PWH with cancer;
leverages stigma reduction interventions at multiple levels to intervene on modifiable mechanisms
of stigma that contribute to negative cancer outcomes among PWH with cancer; and promotes
research in domestic and international contexts, focusing on regions in which the HIV-cancer
burden is elevated. 

Additional Information:
The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer
(R01 Clinical Trials Optional)

Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications

This funding opportunity announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas in HIV/AIDS research related to coinfections, comorbidities, and complications.

Additional Information:
Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1-Clinical Trial Optional)

Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries

The goals of this FOA is to solicit R01 applications for up to 3 years of support to develop and test interventions to reduce the impact of HIV-associated stigma on the prevention and treatment of HIV infection and/or AIDS, and the quality of life of People Living with HIV/AIDS (PLWH). The FOA will also support interventions to address the multiple intersecting stigmas and measurement of stigmas at individual levels. For example support intervention research on strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections.

Additional Information:
Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R01 Clinical Trial Optional)

HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions

The goals of this program are to support locally relevant research in critical areas of HIV- associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity, and to build a network of researchers both within and across LMICs to address this critical burden. NCI is interested in research projects aimed at identifying specific contributions of HIV infection and its potential interaction with other pathogens towards the development and pathogenesis of cancer, or provide information on the clinical outcomes in people living with HIV and cancer.

Additional Information:
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)

Notice of Special Interest (NOSI): Research on HIV-associated Malignancies

The purpose of this Notice of Special Interest (NOSI) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), which are now a leading cause of death of people with HIV (PWH). The NOSI calls for proposals that seek to identify specific contributions to HIV infection and it potential interaction with other oncogenic pathogens on the development and pathogenesis of these cancers, including studies that provide new information on the clinical outcomes of such cancers in PWH. 

The purpose of this NOSI is therefore aligned with OAR priorities of AIDS research and is specifically launched to foster cancer-focused research that addresses important gaps in knowledge for the control and treatment of cancer and cancer-related comorbidities among PWH. This is a continuation of NOT-CA-20-022,  "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers, which expired on January 8, 2023 , and is entitled, “Research on HIV-associated malignancies ” to reflect the most recent Office of AIDS Research priority guidelines.

Multidisciplinary Studies of HIV/AIDS and Aging

This initiative solicits applications at the intersection of HIV and aging.  NCI is interested in studies that help to understand how aging in the presence of chronic HIV infections affects risk, spectrum and biology of cancer.

Additional Information:
Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)